key: cord-0877033-fza17hdo
authors: Li, S. S.; Esmail, S.; Knauer, M.; Abdoh, H.; Chin-Yee, B.; Lowes, L.; Voss, C.; Hedley, B.; Bhayana, V.; Chin-Yee, I.; Seitova, A.; Hutchinson, A.; Yusifov, F.; Skarina, T.; Evdokimova, E.; Ackloo, S.; Stogios, P.
title: Rapid and accurate point-of-care testing for SARS-CoV2 antibodies
date: 2020-12-02
journal: nan
DOI: 10.1101/2020.11.30.20241208
sha: 81b6602359154e9baacc23a3b9700c39939f30cc
doc_id: 877033
cord_uid: fza17hdo

The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has grown into worst public health crisis since the 1918 influenza pandemic. As COVID-19 continues to spread around the world, there is urgent need for a rapid, yet accurate antibody test to identify infected individuals in populations to inform health decisions. We have developed a rapid, accurate and cost-effective serologic test based on antibody-dependent agglutination of antigen-coated latex particles, which uses ~5 ul plasma and takes <5 min to complete with no instrument required. The simplicity of this test makes it ideal for point-of-care (POC) use at the community level. When validated using plasma samples that are positive or negative for SARS-CoV-2, the agglutination assay detected antibodies against the receptor-binding domain of the spike (S-RBD) or the nucleocapsid (N) protein of SARS-CoV-2 with 100% specificity and ~98% sensitivity. Furthermore, we found that the strength of the S-RBD antibody response measured by the agglutination assay correlated with the efficiency of the plasma in blocking RBD binding to the angiotensin converting enzyme 2 (ACE2) in a surrogate neutralization assay, suggesting that the agglutination assay may be used to identify individuals with virus-neutralizing antibodies. Intriguingly, we found that >92% of patients had detectable antibodies on the day of positive viral RNA test, suggesting that seroconversion may occur earlier than previously thought and that the agglutination antibody test may complement RNA testing for POC diagnosis of SARS-CoV-2 infection.

INTRODUCTION 46 47 Development of rapid point-of-care COVID-19 diagnostics for use at the community level 48 remains a top priority in the global response to the COVID-19 pandemic 1 . While capacity for 49 detecting SARS-CoV-2 based on nucleic acid amplification (NAAT) has grown immensely 50 and enabled effective public health responses, serologic testing for virus specific antibodies 51 has not gained the same widespread application, due to concerns over sensitivity, specificity, 52 cost and turn-around time 1,2 . Although NAAT is the current gold standard for diagnosing 53 acute infection, it is not effective in identifying individuals who have recovered from 54 previous infection 3 . Given that approximately 40% of infected individuals remain 55 asymptomatic 1,4,5 , large-scale antibody testing could help better establish the true extent of 56 the COVID-19 pandemic, identifying disease hotspots and high-risk populations to enable 57 more effective isolation and contact tracing 1,3,6 . Moreover, antibody testing may identify 58 individuals with a strong neutralizing antibody response who may be suitable donors for 59 convalescent plasma/serum therapy for the treatment of those with severe symptoms 7 . 60 61 To date, a number of antibody tests have been approved for emergency use in the US and 62

Europe. These tests detect the IgG, IgM or IgA antibody against the spike (including the 63 receptor binding domain, RBD) or nucleocapsid (N) protein of the SARS-CoV-2 virus by 64 enzyme-linked immunosorbent assay (ELISA) 3 . ELISA-based antibody tests, which can be 65 qualitative or quantitative, require specialized instruments and are usually performed in a lab 66 by a trained technician. The sensitivity and specificity of different ELISA kits vary widely [8] [9] [10] . 67

To enable point-of-care (POC) testing, several rapid diagnostic tests (RDTs) based on lateral 68 flow have been developed. Although the RDTs reduced the time of the antibody test to 10-30 69 minutes from 2-5 hours (for ELISA), they generally suffer from decreased sensitivity and 70 specificity compared to ELISA-based assays 1,11-13 . 71 72 To address the pressing need for a simple, rapid, yet accurate antibody test 1 , we resorted to the 73 tested-and-proven serology method of agglutination that has been used in blood typing and 74 antibody testing [14] [15] [16] . We show here that the agglutination of red blood cells (RBCs) or latex 75 particles induced by specific antigen-antibody interaction affords a highly sensitive and 76 accurate assay for SARS-CoV-2 antibodies. We validated the antibody assay based on latex 77 particle agglutination using 169 plasma samples that were tested positive for SARS-CoV-2 by 78 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 2, 2020. ; https://doi.org/10.1101/2020.11.30.20241208 doi: medRxiv preprint

The agglutination-based antibody assay produced 100% specificity and 97-98.2% sensitivity. 80

Because this simple assay requires no instrument and generates results in 2 minutes, it has the 81 potential to be used as a POC or at-home test. Agglutination of RBCs is widely used in blood typing whereas latex particle agglutination 88 assays have been used to detect antibodies against a variety of different viruses. We sought to 89 establish whether either or both approaches could be adapted for SARS-CoV-2 antibody 90 testing. In principle, coating the RBCs or the latex particles with a SARS-CoV-2 specific 91 antigen would enable their respective agglutination by the corresponding antibody ( Fig. 1) . 92

To explore this notion, we labelled Group O (R2R2) RBCs carrying the D antigen with the 93 spike RBD (S-RBD) or the RNA binding domain of the nucleocapsid (N-RBD) protein 94 through streptavidin-biotin mediated coupling (Figs. S1 & S2, see Materials and Methods for 95 details). Incubating the antigen-coated RBCs with COVID-19 + plasma led to robust 96 agglutination whereas the COVID-19plasma failed to induce RBC agglutination, suggesting 97 that the aggregation of the S-RBD/N-RBD-coated RBCs may be used to detect antibody 98 response to SARS-CoV-2 (Fig. S2) . 99 100 To develop a cost-effective agglutination assay, we next investigated if latex particles were a 101 suitable substitute for the RBCs. To this end, we coated latex particles with recombinant 102 S-RBD or the full-length nucleocapsid (N) protein (Fig. S1 ). The antigen coated latex beads 103 were first tested with a monoclonal anti-S-RBD and a polyclonal anti-nucleocapsid antibody. 104

Upon incubating with the corresponding antibody, the antigen-coated latex particles formed 105 clumps within two minutes. Importantly, the area of clump formation grew larger with 106 increasing antibody concentrations (Fig. S3 ). Although latex agglutination was commonly 107 used as a qualitative assay, it is possible to determine the degree of agglutination based on the 108 area of clump formation via image analysis. As shown in Fig. 2 , the percentage of 109 agglutination for both the S-RBD-and N-coated latex particles increased when an 110 incremental amount of anti-S-RBD or anti-N antibody was added. Fitting the data to Hill's 111 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 2, 2020. ; https://doi.org/10.1101/2020.11.30.20241208 doi: medRxiv preprint equation yielded Hill's coefficient of 1.7 for the former and 1.8 for the latter. This suggests 112 that the antibody-induced agglutination of latex particles is a cooperative event (Fig. 2A&B) . 113 114 We next examined if the latex agglutination assay could be used to gauge COVID-19 115 antibody response. Using plasma samples from patients tested positive for SARS-CoV-2 by 116 NAAT and confirmed for strong antibody response by ELISA, we found that the patient 117 plasma samples were not only capable of inducing agglutination of the S-RBD-or N-coated 118 latex particles, they did so in a concentration-dependent manner. As shown in Fig. 2C&D , the 119 extent of agglutination decreased as the plasma was diluted, indicating that the agglutination 120 assay may be used to estimate antibody titer as in an ELISA-based antibody test. 121

The latex agglutination-based antibody assay showed high sensitivity and specificity 123 124

To validate the antibody test based on latex particle agglutination, we carried out 125 agglutination assays for 290 residual plasma samples from individuals that were tested 126 positive (169) or negative (121) for virus RNA by the Roche cobas SARS-CoV-2 test 9 . To 127 assess specificity, we also included 100 virus-naïve samples banked in 2018 in our 128 agglutination assay. None of the 121 SARS-CoV-2or the 100 Pre-COVID-19 plasma 129 samples was capable of promoting the agglutination of either the S-RBD-or N-coated latex 130 particles, indicating 100% specificity for the agglutination assay (Table 1 ). In contrast, of the 131 169 SARS-CoV-2 + plasma samples tested, 166 (98.2%) promoted agglutination in response 132 to the S-RBD antigen and 164 (97%) to the N antigen, with overall sensitivity of 98.2%. We 133 compared the latex agglutination assay with the Euroimmune IgG test for the S antibody and 134 the Roche Elecsys® Total assay for the N antibody using the same set of SARS-CoV-2 + 135 plasma samples and found that the latex agglutination assay outperformed both ELISA-based 136 antibody tests ( Table 2 ). The agglutination assay also exhibited better specificity than either 137 ELISA kit ( Table 2) . Quantification of the agglutination data showed that the COVID-19 + 138 group is significantly different from the COVID-19or pre-COVID-19 group, indicating that 139 the latex agglutination assay effectively distinguished SARS-CoV2 + from SARS-CoV2 -140 individuals (Fig. 3A&B) . 141 142 Based on the background signals of the COVID-19samples (0-4% agglutination for both 143 S-RBD-and N-coated latex particles), we set 5% agglutination as the cut-off for antibody 144 positivity. To facilitate the use of the latex agglutination assay as a simple, semi-quantitative 145 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 2, 2020. ; https://doi.org/10.1101/2020.11.30.20241208 doi: medRxiv preprint antibody test, we developed a numerical scoring system for antibody response. We assigned 146 the scores 1, 2, 3 and 4 to samples that produced 5-25%, 25-50%, 50-75% and >75% 147 agglutination, respectively (Fig. S4 ). We found that this scoring scheme effectively 148 distinguished samples with strong antibody response from those with medium or weak ones 149 (Fig. 3C&D ). The agglutination score may be readily assigned by visual inspection and 150 comparing to reference wells containing a predetermined amount of pure anti-S-RBD or 151 anti-N antibody (Fig. S3) . We noted that the agglutination assay detected antibody response in >92% plasma samples 176 collected on the day of SARS-CoV2 + diagnosis by NAAT and in 100% samples on day 2 and 177 afterward. This is in stark contrast to the 47% to 83% sensitivity for ELISA-based antibody 178 tests on samples collected within 7 days of positive NAAT 9 . The superb sensitivity of the 179 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 2, 2020. ; https://doi.org/10.1101/2020.11.30.20241208 doi: medRxiv preprint latex agglutination assay suggests that it may be used to detect antibody response in the early 180 stage of virus infection and monitor its dynamic changes over time 12,20,21 . Using serial blood 181 samples from SARS-CoV-2 + patients, we compared the changes in the S-RBD and N 182 antibody responses between days 1 and day 3 (Fig. 4C&D ). We found that the majority of 183 patients showed detectable S-RBD and/or N antibodies on NAAT + day 1. Moreover, the 184 antibody titer increased significantly on day 3 compared to day 1. Because it is not possible 185 to determine how long these patients had contracted the virus prior to the NAAT test, 186 seroconversion might have occurred for some on the day of diagnosis. Nevertheless, we were 187 able to detect anti-S-RBD or anti-N antibodies on day 3 for several patients who showed no 188 detectable antibody on day 1, suggesting seroconversion occurred rapidly in these patients 4 . 189

Taken together, these data suggest that the latex agglutination assay may be used to diagnose immunity against SARS-CoV-2. Such information will be invaluable to inform public health 206 decisions, both for directing resource allocation and determining response to vaccination. 207 208 While most serology tests used in the clinic are specific for a specific antibody isoform, IgG, 209

IgM or IgA, the latex agglutination antibody assay is, in principle, isotope-independent 11 . 210

This may contribute to its high sensitivity, especially on samples collected in the early phase 211 of infection when IgG isotope switching has not yet occurred. It has been shown that the IgM 212 antibody response proceeds that of IgG 3,11 , and the pentameric architecture of IgM may make 213 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 2, 2020. ; https://doi.org/10.1101/2020.11.30.20241208 doi: medRxiv preprint it a stronger promoter of agglutination than IgG. Moreover, the agglutination assay detects 214 antibodies against the spike (S) and the nucleocapsid (N) in parallel whereas most existing 215 assays are specific for either protein. These factors explain why the agglutination assay could 216 detect antibody in >92% plasma samples collected on the day of NAAT + diagnosis and 100% 217 on day 2 and onwards whereas other antibody tests were less sensitive. The ability of our 218 assay to detect antibodies at the early stages of infection suggests that it may be used to 219 complement or confirm the diagnosis based on NAAT, which is prone to false positives or 220 false negatives especially when done only once 23 . 221 222 Several features of the agglutination assay make it an ideal candidate for POC or at-home 223 antibody testing. First, the assay is highly sensitive and accurate, with 100% specificity and 224

~98% sensitivity on the samples tested in this study. Importantly, it detected antibodies in >92% 225 COVID-19 patients on the day of diagnosis. This sensitivity rivals that of NAAT tests 23 . 226

Second, the agglutination test is fast. It takes two minutes from mixing the plasma with the 227 latex particles to getting the result. Third, the agglutination assay is simple to run and 228 instrument-free. As the formation of latex bead clumps is easy to identify by the naked eye, the 229 test may be performed without extensive specialized training. Fourth, because the 230 agglutination assay takes only ~5 μl plasma, it may be developed into a finger prick blood test 231 suitable for at-home use. Finally, the low cost of the latex agglutination assay makes it 232 universally affordable and ideal for antibody testing at the community or population level, in 233 high-and low-resource settings alike. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 2, 2020. ; https://doi.org/10.1101/2020.11.30.20241208 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 2, 2020. ; https://doi.org/10.1101/2020.11.30.20241208 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 2, 2020. ; https://doi.org/10.1101/2020.11.30.20241208 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 2, 2020. ; https://doi.org/10.1101/2020.11.30.20241208 doi: medRxiv preprint calculated based on unpaired Student's t-test with Welch's correction. 287 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 2, 2020. ; https://doi.org/10.1101/2020.11.30.20241208 doi: medRxiv preprint 316 Recombinant N-RBD was expressed in E. coli BL21(DE3)-Gold. Ni-NTA chromatography 317 and size exclusion chromatography-Superdex S200 was used to purify N-RBD. The tag was 318 cleaved using TEV followed by dialysis. The N-RBD protein was resuspended in 0.1 M NaCl, 319 20 mM HEPES pH 7.5 and stored at -80 o C until use. Recombinant nucleocapsid (residues 320 1-419) was obtained from RayBiotech (Cat #230-01104). Protein purity was confirmed by 321 SDS-PAGE (Fig. S1) . 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 2, 2020. ; https://doi.org/10.1101/2020.11.30.20241208 doi: medRxiv preprint For the agglutination assay, 5 μl plasma was mixed with 25 μl antigen-coated beads (2.5%, 348 w/v) per assay. The agglutination was allowed to proceed for 2 min at room temperature 349 before imaging with a camera. The relative degree of agglutination induced by the 350 SARS-CoV-2 antibody was measured by the area of clump formation based on the 351 corresponding image. Agglutination data analyses were performed using qualitative and 352 semi-quantitative assessments. For semi-quantification of agglutination, the image analysis 353 software Qupath (v0.1.2) was used (https://qupath.github.io/) and quantification was done by 354 calculating the percentage of agglutination based on estimated agglutination/clumps area 355 (mm 2 ) relative to the total latex reaction area. In qualitative assessments, agglutination 356 intensity was inspected visually, and agglutination score was assigned (i.e. 1, 2, 3 and 4). 357

Specifically, 1 corresponds to small clumps with ~25% agglutination, 2 (~50% agglutination), 358 3 (~75% agglutination), and 4 (large clumps that forms in less than 1 min with ~100% 359 agglutination). Based on data from the COVID-19 negative samples (including NAAT 360 negative and samples collected in 2018), the cut-off for positivity was set to 5% of 361 agglutination. 362

The complex was centrifuged at 1000g for 2 min to remove unbound anti-D-IgG streptavidin and 378 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 2, 2020. ; https://doi.org/10.1101/2020.11.30.20241208 doi: medRxiv preprint was then resuspended in the same RBC diluent. RBC-anti-D-IgG-streptavidin was then 379 conjugated with either biotin-S-RBD or biotin-N-RBD for 15 min at room temperature. The 380 RRBC-anti-D-sterptaviding-biotin-S-RBD/N-RBD was stored at 4 °C until use. The RRBC 381 agglutination assay was carried out in the same way as for latex agglutination described and COVID-19samples were analyzed using unpaired t-test with Welch's correction (no 412 assumption of equal SD between two groups). Changes in agglutination for samples before 413 and after heat-inactivation were analyzed by paired t-test. Spearman's correlation rank was 414 done to study correlation between antibody titter and ACE2:S-RBD neutralization efficiency. 415 416 417 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 2, 2020. ; https://doi.org/10.1101/2020.11.30.20241208 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 2, 2020. ; https://doi.org/10.1101/2020.11.30.20241208 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 2, 2020. ; Figure S3 . Agglutination of blue latex particles in response to different concentrations of antibody (IgG) against the nucleocapsid (aN) or S-RBD (aS-RBD). Anti-S-RBD (monoclonal, NBP2-90980) was obtained from Novus Biologicals; Anti-Nucleocapsid (polyclonal, PA5-81794) was from ThermoFisher Scientific.

(IgG) 0 (µg/ml) 5 (µg/ml) 2.5 (µg/ml) 1 (µg/ml) 7.5 (µg/ml) 0 1 2 3 4

Esmail et al.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 2, 2020. ; https://doi.org/10.1101/2020.11.30.20241208 doi: medRxiv preprint Figure S4 . Representative images of agglutination induced by plasma with different agglutination scores. Shown are five samples with distinct agglutination scores (0-4) in the nucleocapsid (aN) (upper row) or the S-RBD antibody (aS-RBD) test (lower row). The scores were assigned as 4 = 75-100% agglutination; 3 = 50-75% agglutination; 2 = 25-50% agglutination; 1 = 5-25% agglutination; 0 (or negative) ≤5% agglutination.

Esmail et al. 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 2, 2020. ; https://doi.org/10.1101/2020.11.30.20241208 doi: medRxiv preprint Esmail et al.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 2, 2020. ; https://doi.org/10.1101/2020.11.30.20241208 doi: medRxiv preprint

Test performance evaluation of SARS-CoV-2 serological assays

Development and clinical application of a rapid IgM-IgG combined 451 antibody test for SARS-CoV-2 infection diagnosis

Whole-blood agglutination assay for on-site detection 454 of human immunodeficiency virus infection

Particle Agglutination Assay for the Detection of Cytomegalovirus Antibody in 458 Patient Serum

Rapid Gel Card Agglutination Assays for Serological Analysis 460

Following SARS-CoV-2 Infection in Humans

Neutralizing Antibodies against SARS-CoV-2 and 463

Ultrapotent human antibodies protect against

SARS-CoV-2 challenge via multiple mechanisms

Convergent Antibody Responses to SARS-CoV-2 Infection in 477

Profile of IgG and IgM antibodies against severe acute respiratory 479 syndrome coronavirus 2 (SARS-CoV-2)

The COVID-19 vaccine development landscape

Effectiveness of tests to detect the presence of SARS-CoV-2 virus, 484 and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic 485 review

Conventional rapid latex 487 agglutination in estimation of von Willebrand factor: method revisited and potential 488 clinical applications